We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Study criticizes journals for leaving out trial details

  • John Schieszer
Sep 1, 2010
Volume: 
19
Issue: 
9
Abstract / Synopsis: 
ABSTRACT: Published trial results fail to offer information that oncologists need for clinical translation.
JOSEPH S. BAILES, MD
JOSEPH S. BAILES, MD
Editor

Randomized controlled trials published in major oncology journals do not consistently report essential therapeutic details necessary for translation to clinical practice, according to a new study by Florida researchers. Based on their findings, the authors are calling for improved reporting from all therapy-based trials to include specific details about performing adjustments for hematologic and organ-specific toxicity.

THOMAS GEORGE, JR., MD

"We're just taking it to the next logical step, which is, 'how do we apply these results to the masses of patients who need to benefit from scientific progress?"
— THOMAS GEORGE, JR., MD

"We were frustrated that we were trying to adjust the therapeutics to the side effects that were occurring in the care of patients and we realized everyone had different styles," said lead author Thomas George, Jr., MD, director of the University of Florida's gastrointestinal oncology program. "For example, a clinician might reduce the dose of chemotherapy if neutropenia was detected, or add growth factors or do some combination thereof—or do nothing. So we would go to the article that established the original regimen to get an answer. We found there was so much variability among providers we could not consistently find the answers."

He said randomized clinical trials improve clinical care via evidence-based results. He noted that guidelines exist for reporting results from randomized clinical trials, but often lack specific details needed for clinical translation. Dr. George and his colleagues identified 10 essential elements of randomized clinical trial reporting, including drug name, dose, route, cycle length, maximum number of cycles, premedication growth factor support, patient monitoring parameters, and dosing adjustments for various toxicities.

The investigators analyzed all therapy-based oncology randomized clinical trials published between 2005 and 2008 in five journals (see Table).

They found that premedication, growth factor support and dose adjustments for toxicities were reported in less than half of the articles and only 30 articles (11%) met the main objective of complete data reporting (all 10 essential elements).

The highest percentages of complete data reporting were found in JNCI (25% of the time; 5/20 articles), followed by Cancer (18%; 5/27 articles), JCO (11%, 18/165 articles), Blood (5%; 1/19 articles); and NEJM (3%; 1/31 articles).

TABLE

Publications analyzed

165 articles in Journal of Clinical Oncology (JCO)

31 articles in New England Journal of Medicine (NEJM)

27 articles in Journal of the National Cancer Institute (JNCI)

19 articles in Blood

20 articles in Cancer

Total: 262 articles

"It just boils down to willpower on the part of the journal editors to agree that this is an important issue," Dr. George said. "I think the scientific community, the publishers, the editors, and even the investigators who conduct the studies have been appropriately focused on justifying the scientific methods and merit of the study. We're just taking it to the next logical step, which is, 'how do we apply these results to the masses of patients who need to benefit from scientific progress?'"

The researchers found that the dose of the drug was almost always reported. However, only 43% of the papers reported what kind of premedication was necessary and only 42% reported how they adjusted dosages if the therapy proved toxic (J Natl Cancer Inst 102:702-705, 2010).

Pages

  • 1
  • 2
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.